<DIV><BR> “<I>Blood Feud</I> rivals <I>A Civil Action</I> for best non-fiction book of the past twenty years.” — John Lescroart, <I>New York Times</I> bestselling author of <I>Damage</I><br><br> Procrit seemed like a biotech miracle, promising a golden age in medical care. Developed in the 1980s by Amgen and licensed to the pharmaceutical giant, Johnson & Johnson, the drug (AKA Epogen and Aranesp) soon generated billions in annual revenue—and still does.<br><br> Mark Duxbury was a J&J salesman who believed in the blood-booster, setting record sales and winning company awards. Then Duxbury started to learn unsavory truths about Procrit and J&J’s business practices. He was fired and filed a whistleblower suit to warn the public.<br><br> When Jan Schlichtman (<I>A Civil Action</I>) learned of Duxbury’s crusade, he signed on. Now, he’s fighting on behalf of cancer patients and for every American who trusts Big Pharma with his life.</div>